What is a bulking agent procedure and when is it typically used?

• A. Surgical removal of urethral tissue.
• B. Injection of material around the urethra to improve sphincter coaptation; used for intrinsic sphincter deficiency or when a sling is contraindicated.
• C. Insertion of a penile implant.
• D. Injection of material around the bladder neck to increase capacity.

Answer: (B)

Bulking agent procedures aim to improve the seal of the urethra by injecting a biocompatible material around the urethral tissue. The added bulk helps the urethra coapt better when pressure rises during activities that provoke leakage, addressing incontinence that stems from intrinsic sphincter deficiency.

This approach is particularly appropriate when intrinsic sphincter deficiency is present or when a sling procedure is contraindicated due to medical factors, prior surgeries, or unfavorable anatomy. The goal is to provide a less invasive option that elevates the closing mechanism of the urethra without more extensive surgery.

The procedure is usually done in an outpatient setting with local or regional anesthesia and cystoscopic guidance, delivering the injectable material at multiple periurethral sites. Common bulking agents include dextranomer/hyaluronic acid and other biocompatible substances, chosen based on patient factors and surgeon experience. Results can vary in durability, and some patients may require repeat injections to maintain continence.

Injecting around the urethra aligns with the intended mechanism. Injecting around the bladder neck to increase capacity does not address urethral closure in the same way and is not the standard approach for bulking incontinence.